Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

NCT04486391 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
3
Enrollment
INDUSTRY
Sponsor class

Stopped Study has voluntarily discontinued due to a change in the company-level development strategy and is not because of any safety concern.

Conditions

Interventions

Sponsor

BeiGene